Quarterly ResultMay 11, 2026, 04:07 PM
Harrow Q1 Revenue $44.2M; Reaffirms FY26 Guidance $350M-$365M
AI Summary
Harrow reported Q1 2026 revenues of $44.2 million, a decrease from $47.8 million in Q1 2025, primarily due to an approximate $8 million non-recurring gross-to-net revenue adjustment related to new VEVYE commercial coverage. Despite this, the company saw record prescription performance for VEVYE and strong demand growth for IHEEZO and TRIESENCE. Harrow reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and expects Q2 revenue between $71 million and $81 million.
Key Highlights
- Q1 2026 total revenues were $44.2 million, down 7.6% year-over-year.
- Q1 2026 net loss was $(27.6) million, compared to $(17.8) million in Q1 2025.
- Q1 2026 Adjusted EBITDA was $(12.7) million, compared to $(2.0) million in Q1 2025.
- VEVYE delivered record prescription performance, with NRx up 25% and TRx up 11% quarter-over-quarter.
- IHEEZO unit demand increased 18% year-over-year, with 82% from retina accounts.
- TRIESENCE unit demand more than doubled year-over-year, up 136%.
- Reaffirmed full-year 2026 revenue guidance of $350 million to $365 million.
- Cash and cash equivalents were $94.6 million as of March 31, 2026.